American Delirium Society
2021 Virtual Annual Conference 

Scientific Discovery to Real World Implementation


June 13-15, 2021 | Virtual

Program Co-Chairs:

Babar Khan, MD, MS 
2021 Program Co-Chair
Immediate Past President, American Delirium Society

Noll Campbell, PharmD, MS 
2021 Program Co-Chair

CLICK HERE to view the brochure.

CLICK HERE to Register

Pre-Conference (PC) pricing is for Sunday, June 13, 2021. Full Conference (FC) pricing includes the Pre-Conference and is for Sunday, June 13 - Tuesday, June 15, 2021

PC ONLY (ADS Member or Non-Member)  $100.00
FC (ADS Member) Physician  $250.00
FC (ADS Member) Non-Physician  $250.00
**FC (Non-Member) Physician $350.00
**FC (Non-Member) Non-Physician  $350.00
FC (ADS Member or Non-Member) Resident  $100.00
FC (ADS Member or Non-Member) Fellow  $100.00
FC (ADS Member or Non-Member) Trainee  $100.00
FC (ADS Member or Non-Member) Student  $100.00

**Includes one-year membership (January 1-December 31, 2021)


Welcome to the American Delirium Society (ADS) 2021 Virtual Annual Conference! We are pleased to host a 3-day meeting experience, which is expected to draw more than 400 investigators, educators and clinicians from all spectrums of healthcare and around the globe! #ADS21Virtual is the destination for professionals dedicated to improving delirium care at every level of their career.

The ADS conference focuses on learning with a diverse group of attendees across many disciplines and countries – each and every one striving to learn together as we improve delirium care across all healthcare settings.

The conference offers more than 20 symposia, workshops and roundtables, multiple abstract sessions, a virtual poster session and a robust all-day pre-conference. Internationally recognized faculty will deliver cutting edge clinical and research presentations encompassing all aspects of delirium care. We are proud to say that there will be something for everyone!

Don’t miss the following important events:

  • A dynamic full-day pre-conference. Through interactive didactic sessions and delirium assessment training, this intense curriculum will provide you with the skills to make important practice changes at your institution.
  • Plenaries from internationally recognized translational, clinical and policy experts.
  • Workshops and roundtables focused on practice improvement, education, research design/biostatistics, NIH funding and translational research.
  • Symposia focused on imaging, biomarkers, ICU practice change, sleep, palliative care, pediatrics and post-operative delirium prevention.
  • The NIDUS investigators will provide an update on their efforts to boost research infrastructure and training.
  • Presentations of oral abstracts moderated by senior investigators in the field.
  • A poster session moderated by experts in the field.

Finally, we wish to acknowledge the hard work and outstanding efforts of the Conference Planning Committee. A full list of committee members can be found below.

We welcome you to the ADS 2021 Virtual Annual Conference and hope you take advantage of all ADS has to offer.

Learning Objectives

  1. Identify evidence-based best practices for recognizing and assessing delirium among patients in hospital, outpatient, and long-term care settings.

  2. Discuss evidence-based preventative and therapeutic strategies for reducing the prevalence and duration of delirium across the continuum of care.

  3. Review novel and innovative strategies to develop, implement, evaluate and sustain health system delirium reduction efforts.

  4. Explain emerging and high-impact research focused on delirium epidemiology, pathophysiology, diagnosis, prevention and treatment.

2021 Conference Planning Committee

Babar Khan, MD, MS

Noll Campbell, PharmD, MS

Andrew Auerbach MD, MPH

Leanne Boehm, RN, PhD, ACNS-BC

Sikandar Khan, DO, MS

Heidi Lindroth, PhD, RN

Kerri Maya, MSL, RN, PHN

Esther Oh, MD, PhD

Mark Oldham, MD

Pratik Pandharipande, MD, MSCI, FCCM

Phillip Vlisides, MD

Christine Waszynski, DNP, APRN, GNP-BC

Thank You to Our 2021 ADS Sponsors


EyeControl is a pioneer of medical technology, specializing in innovative communication solutions that address unmet healthcare needs. We implement disruptive AI-technologies that connect people and bridge information barriers, facilitating better medical care and decision-making.

Our eye-tracking wearable and smart platforms empower comprehensive, round-the-clock, bi-directional connectivity between patients with communication difficulties, their families, and medical teams.

Using adaptive, ML-based pattern recognition, eye gestures are analyzed and converted to real-time communication and actionable clinical data for patients with various levels of cognition.

Established in 2016 by individuals, who share unique personal connections to Locked-in patients, EyeControl is a privately held, rapidly growing startup. Recognized for its cutting-edge medical innovation, the company is supported by the European Innovation Council, Israel Innovation Authority, investors and advisors representing various sectors.

The device is FDA listed, CE marked, ISO certified, AMAR registered, and HIPAA compliant; it is federally reimbursed in Israel, the UK, and the US. Clinical trials validating its efficacy in detecting and mitigating Delirium are underway in Israel and the US.



Kaiser Permanente

Kaiser Permanente is committed to helping shape the future of health care.
We are recognized as one of America's leading health care providers and
not-for-profit health plans.
Founded in 1945, Kaiser Permanente has a mission to provide high-quality,
affordable health care services and to improve the health of our members
and the communities we serve. We currently serve more than 12.2 million
members in 8 states and the District of Columbia.


Prolira Deltascan

Prolira developed DeltaScan® for you, a revolutionary medical device that objectively monitors the brain state of patients. In just a few minutes, the patient’s brain is assessed for signs of illness (acute encephalopathy and delirium).

Monitoring the brain state of hospitalized patients is as important monitoring other vital organs like the heart or lungs. Until now this was difficult, as only subjective checklists with limited performance in routine care settings were available. With DeltaScan®, the brain state is objectively determined at the bedside using breakthrough EEG technology. 

DeltaScan’s single use Patch acquires the brain signals and the Monitor analyses these signals with smart Artificial Intelligence (AI) algorithms. DeltaScan provides an easy-to-interpret score between 1 and 5, which supports effective medical treatment. DeltaScan is a CE marked device, and is already in use in 20 frontrunner hospitals in Europe. Early next year DeltaScan will become available in the USA.

CE Credit

Physicians / Nurses / Pharmacists

In support of improving patient care, this activity has been planned and implemented by the American Delirium Society and Sutter Health. Sutter Health, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.